AI Article Synopsis
- Orofacial dyskinesia, a movement disorder affecting the face, has rarely been linked to antibiotics, but this report highlights a case involving the fourth-generation fluoroquinolone moxifloxacin.
- A 58-year-old woman developed orofacial dyskinesia after taking moxifloxacin for acute bronchitis, demonstrating that even newer antibiotics can have similar side effects as older ones.
- The patient's symptoms improved significantly after stopping moxifloxacin and receiving clonidine treatment, suggesting a need for awareness of potential movement disorders with fluoroquinolone use, regardless of kidney function.
Article Abstract
Background: Orofacial dyskinesia is rarely reported with antibiotics. Among antibiotics, third-generation fluoroquinolones are known to cause movement disorders. We report the first patient who developed orofacial dyskinesia after taking a fourth-generation fluoroquinolone, namely, moxifloxacin.
Methods: The patient is a 58-year-old woman who was treated with moxifloxacin for acute bronchitis. She developed orofacial dyskinesia involving the tongue, lips, and facial muscles after treatment.
Results: Discontinuation of moxifloxacin and treatment with clonidine resulted in significant reduction of orofacial dyskinesia over the period of 8 to 12 weeks. A review of literature shows reports of a variety of involuntary movements with third-generation fluoroquinolones, mostly manifesting in patients with impaired renal and kidney function.
Conclusions: The fourth-generation fluoroquinolone moxifloxacin can cause orofacial dyskinesia like third-generation fluoroquinolone antibiotics and in a patient with normal renal and liver function.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/WNF.0b013e31826ba0eb | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!